Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 2-(4-benzylpiperidino)-1-(4-hydroxyphenyl)-2-methyl-1-ethanol
2. 4-benzyl-alpha-(p-hydroxyphenyl)-beta-methyl-1-piperidineethanol
3. 61 91 Rc
4. Alpha-(4-hydroxyphenyl)-beta-methyl-4-(phenylmethyl)-1-piperidine Ethanol
5. Ifenprodil
6. Ifenprodil Hydrochloride
7. Ifenprodil Hydrochloride, (+-)-isomer
8. Ifenprodil Tartrate
9. Ifenprodil Tartrate (1:1), (r*,s*)-(+-)-(r-(r*,r*))-isomer
10. Ifenprodil Tartrate (1:1), (r-(r*,r*))-isomer
11. Ifenprodil Tartrate (2:1), (r-(r*,r*))-isomer
12. Ifenprodil, (r*,s*)-(+-)-isomer
13. Ifenprodil, Tartrate(r-(r*,r*))-isomer
1. Dilvax
2. Ifenprodil Tartrate
3. Ifenprodil L-(+)-tartrate
4. 66157-43-5
5. Cerocral
6. Validex
7. 4-[2-(4-benzylpiperidin-1-yl)-1-hydroxypropyl]phenol;(2r,3r)-2,3-dihydroxybutanedioate
8. Ifenprodil Tartrate (2:1)
9. Ifenprodil L-(+)-tartrate (2:1)
10. 2-(4-benzyl-piperidino)-1-(4-hydroxyphenyl)-1-propanol Tartrate (2:1)
11. 4-benzyl-alpha-(p-hydroxyphenyl)-beta-methyl-1-piperidineethanol Tartrate
12. 4-benzyl-alpha-(p-hydroxyphenyl)-beta-methyl-1-piperidine-ethanol-(l)-(+)-tartrate
13. Piperidineethanol, Alpha-(4-hydroxyphenyl)-beta-methyl-4-(phenylmethyl)-, Tartrate (2:1)
14. 1-piperidineethanol, 4-benzyl-alpha-(p-hydroxyphenyl)-beta-methyl-, Tartrate (salt) (2:1)
Molecular Weight | 799.0 g/mol |
---|---|
Molecular Formula | C46H58N2O10-2 |
Hydrogen Bond Donor Count | 6 |
Hydrogen Bond Acceptor Count | 12 |
Rotatable Bond Count | 11 |
Exact Mass | 798.40914605 g/mol |
Monoisotopic Mass | 798.40914605 g/mol |
Topological Polar Surface Area | 208 Ų |
Heavy Atom Count | 58 |
Formal Charge | -2 |
Complexity | 476 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 2 |
Undefined Atom Stereocenter Count | 4 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 3 |
Excitatory Amino Acid Antagonists
Drugs that bind to but do not activate excitatory amino acid receptors, thereby blocking the actions of agonists. (See all compounds classified as Excitatory Amino Acid Antagonists.)
Adrenergic alpha-Antagonists
Drugs that bind to but do not activate alpha-adrenergic receptors thereby blocking the actions of endogenous or exogenous adrenergic agonists. Adrenergic alpha-antagonists are used in the treatment of hypertension, vasospasm, peripheral vascular disease, shock, and pheochromocytoma. (See all compounds classified as Adrenergic alpha-Antagonists.)
Vasodilator Agents
Drugs used to cause dilation of the blood vessels. (See all compounds classified as Vasodilator Agents.)
ABOUT THIS PAGE
A Cerocral manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Cerocral, including repackagers and relabelers. The FDA regulates Cerocral manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Cerocral API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Cerocral supplier is an individual or a company that provides Cerocral active pharmaceutical ingredient (API) or Cerocral finished formulations upon request. The Cerocral suppliers may include Cerocral API manufacturers, exporters, distributors and traders.
click here to find a list of Cerocral suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Cerocral Drug Master File in Japan (Cerocral JDMF) empowers Cerocral API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Cerocral JDMF during the approval evaluation for pharmaceutical products. At the time of Cerocral JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Cerocral suppliers with JDMF on PharmaCompass.
Cerocral Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Cerocral GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Cerocral GMP manufacturer or Cerocral GMP API supplier for your needs.
A Cerocral CoA (Certificate of Analysis) is a formal document that attests to Cerocral's compliance with Cerocral specifications and serves as a tool for batch-level quality control.
Cerocral CoA mostly includes findings from lab analyses of a specific batch. For each Cerocral CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Cerocral may be tested according to a variety of international standards, such as European Pharmacopoeia (Cerocral EP), Cerocral JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Cerocral USP).
LOOKING FOR A SUPPLIER?